Purchase this article with an account.
Zsofia Kolkedi, Adrienn Horváth, Zsolt Biro; The results of intravitreal bevacizumab (Avastin) therapy in patients with retinal venous occlusion. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1811.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the functional and anatomical results of anti-VEGF (bevacizumab) treatment in patients with retinal venous occlusion.<br />
Retrospective data analysis of 20 patients (10 men, 10 women, mean age 62 years) suffering from retinal venous occlusion (10 CRVO, 10 BRVO) treated with intravitreal bevacizumab injections at the Department of Ophthalmology, Faculty of Medicine, University of Pécs, Hungary between July 2012 and May 2014. The mean follow-up time was 12 (5-22) months. The visual acuity was determined by ETDRS chart, the retinal thickness by SD OCT (Topcon).
The mean best corrected visual acuity improved by 15 ETDRS letters (from 55 to 70). The central retinal thickness decreased from 521 µms to 322 µms in average by the end of the follow-up period. The mean number of injections was 7 during the follow-up time.
Intravitreal bevacizumab therapy in patients with retinal venous occlusion showed functional and anatomical results during one year follow up.
This PDF is available to Subscribers Only